Day: July 2, 2021

Four Seasons Education Files Fiscal Year 2021 Annual Report on Form 20-F

SHANGHAI, July 3, 2021 /PRNewswire/ — Four Seasons Education (Cayman) Inc. (“Four Seasons Education” or the “Company”) (NYSE: FEDU), a leading Shanghai-based educational company dedicated to providing comprehensive after-school education services with a focus on high-quality math education, today announced that it filed its annual report on Form 20-F for the fiscal year ended February […]

Autohome Inc. Announces Management Change

BEIJING, July 3, 2021 /PRNewswire/ — Autohome Inc. (NYSE: ATHM; HKEX: 2518) (“Autohome” or the “Company”), the leading online destination for automobile consumers in China, today announced that Mr. Jun Zou has notified the Company that he intends to resign as chief financial officer due to his other personal commitments. The effective date of Mr. […]

Country Garden Releases 2020 Sustainability Report

FOSHAN, China, July 2, 2021 /PRNewswire/ — On June 28, Chinese property developer Country Garden (HK:2007) released its 2020 Sustainability Report, systematically demonstrating its latest practices and achievements in the Environmental, Social and Governance (ESG) field. Creating a better life by promoting innovation in technology According to the report, in recent years, Country Garden has actively transformed […]

INTERSPORT Strengthens Business Relationship With Intersocks and Sells The Athlete’s Foot to Arklyz Group, Owner of Intersocks

Global performance sports retailer INTERSPORT International Corporation (IIC) strengthens its core business and has agreed on a deal to sell 100% of the highly successful The Athlete’s Foot (TAF) retail & e-commerce network to Arklyz Group AG (Arklyz) – owner of Intersocks. As part of the deal, IIC and Arklyz have agreed on a close […]

Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer

SUZHOU, China, July 2, 2021 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that promising anti-tumor responses have been observed in the ongoing TST001 (anti-Claudin18.2 monoclonal antibody) trials. TST001 is currently in dose-escalation study as monotherapy in both […]

Back To Top